CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present early clinical and laboratory data on the potential role of terminal complement inhibition with Soliris® (eculizumab) for the treatment of a subset of kidney transplant patients who are at high risk for antibody-mediated rejection (AMR) of their grafts. These data will be included in three oral sessions and one poster presentation at the American Transplant Congress being held May 30 to June 2, 2009 at the Hynes Convention Center in Boston. This research includes interim results from an investigator-initiated study of Soliris® for the prevention of AMR in this sub-population of kidney transplant patients.
